Thermo Fisher to Offer Complete Cannabis Testing Solutions



Thermo Fisher Scientific

Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.

The above chart shows details about Thermo Fisher’s Cannabis Testing Solutions.

Article continues below advertisement

About the Cannabis Testing Solutions

New cannabis laws in Canada are set to be implemented in October 2018. Thermo Fisher offers end-to-end solutions for analyzing the safety, potency, and purity of cannabis compliant with Health Canada’s testing standards to contract research organizations, regulatory laboratories, licensed dealers, producers, and suppliers.

Thermo Fisher showcased products including consumables, instruments, and software at the Grow Up Conference and Expo 2018 in Ontario on September 7 and 8.

The company also plans to host a complimentary educational seminar series, “Cannabis Testing One-Stop Analytical Solutions Seminar Series” across Canada between October 9 and October 18. The first seminar will be held in Vancouver. These seminars will cover the following points:

  • regulatory updates from Health Canada
  • potency testing for cannabis
  • targeted and non-targeted pesticide analysis
  • rapid mycotoxin analysis
  • heavy metal analysis to ppb levels
  • analytical software and cloud laboratory information management system (or LIMS) solutions
  • sample preparation tips for improving results

Scientists can perform tests for microbial contaminants and disintegration, tetrahydrocannabinol content, and cannabinoid profiling, nutritional information, and water using Thermo Fisher’s Cannabis workflows. These solutions can be combined with cloud-connected LIMS for information management and regulatory compliances.

The iShares US Healthcare ETF (IYH) holds 2.5% of its total investments in Thermo Fisher Scientific (TMO), 3.4% in Medtronic (MDT), 1.4% in Stryker (SYK), and 1.8% in Becton Dickinson (BDX).


More From Market Realist